Efficacy of combined surgery and <sup>125</sup>I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Wu, Zhiyuan; Wu, Wenjie; Zheng, Lei; Huang, Mianliang; Shi, Yan; Lv, Xianli; Liu, Shuming; Zhang, Jianguo; Zhang, Jie

doi:10.1002/hed.25813

Cited by 10 publications

(18 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High-grade tumors are generally treated with surgical excision with wide margins or neck dissection followed by postoperative radiotherapy[ 13 ]. Furthermore, Wu et al[ 20 ] reported that postoperative adjuvant 125 I seed brachytherapy appears to be an effective and safe treatment option for MEC of the parotid gland with a clinically node-negative neck, especially when the tumor is of low or intermediate grade.…”

Section: Discussionmentioning

confidence: 99%

Mucoepidermoid carcinoma in the infratemporal fossa: A case report

Zhang

Yang

2020

WJCC

View full text Add to dashboard Cite

BACKGROUND Mucoepidermoid carcinoma is the most common primary epithelial salivary gland malignancy. It mostly occurs in the major or intraoral minor salivary glands but rarely in the infratemporal fossa. Here, we present a case of aggressive mucoepidermoid carcinoma in the infratemporal fossa with neck lymph node metastasis and also discuss diagnostic and treatment strategies. CASE SUMMARY A 39-year-old woman with a mass located in the right submandibular area presented to our department. Physical examination revealed lymphadenopathy on the right submandibular side measuring 2.5 cm × 3 cm that was hard and had poor mobility. Results of nasal endoscopy were unremarkable. Ultrasound examination revealed an enlarged lymph node at level II of the right side. Fine needle aspiration cytology of the metastatic lymph node revealed malignant cells with infection. Contrast-enhanced computed tomography revealed an enhancing ill-defined soft tissue mass in the right infratemporal region. Positron emission tomography/computed tomography revealed hyperintensity in the right infratemporal fossa along with lymphadenopathy at level II of the right-side lymph node. The patient underwent extended resection of the primary tumor, and ipsilateral radical neck dissection was also completed. Hematoxylin-eosin staining and immunohistochemistry revealed a high-grade mucoepidermoid carcinoma. No signs and symptoms of recurrence of the neoplasm were present after 20 mo of follow-up. CONCLUSION Positron emission tomography/computed tomography play a key role in primary tumor localization. Furthermore, histopathology and immunohistochemistry play pivotal roles in disease diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Mucoepidermoid carcinoma in the infratemporal fossa: A case report

Zhang

Yang

2020

WJCC

View full text Add to dashboard Cite

show abstract

“…Another study reported that the median LTPFS time (14 vs. 9 months, p < 0.001) of I-125 BT in treating distant metastases in the oral and maxillofacial region compared to EBRT was also higher ( 86 ). Moreover, several single-arm clinical studies suggested that I-125 BT performed exceptionally well in various head and neck cancers, including primary mucoepidermoid carcinoma of the parotid gland (10-year OS rate of 95.8%), adenoid cystic carcinoma (ACC) involving the skull base (3-year OS rate of 62.6% and 3-year PFS rates of 46.4%), and salivary gland carcinomas of the lip and buccal mucosa (10-year LC rate of 82.9% and 10-year OS rate of 77.8%) ( 111 – 113 ). One study reported that the use of I-125 BT in non-squamous carcinoma results in a better outcome compared to squamous cell carcinoma ( 2 ).…”

Section: I-125 Brachytherapy In Solid Tumorsmentioning

confidence: 99%

“…TACE Median OS time: 11 vs. 9 months, P=0.022. Median biliary patency time: 6 vs. 4 months, P=0.Mean PFS time: 7.1 vs. 3.6 months; P<0.001; Mean OS time: 16.9 VS. 12.PFS time: 8 vs. 5.5 months; P < 0.05; LCR time: 10 vs. 6.2 months; P< 0.parotid gland (10-year OS rate of 95.8%), adenoid cystic carcinoma (ACC) involving the skull base (3-year OS rate of 62.6% and 3-year PFS rates of 46.4%), and salivary gland carcinomas of the lip and buccal mucosa (10-year LC rate of 82.9% and 10-year OS rate of 77.8%)(111)(112)(113).…”

mentioning

confidence: 99%

Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions

Wei

Mengyuan

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Radioactive iodine-125 (I-125) is the most widely used radioactive sealed source for interstitial permanent brachytherapy (BT). BT has the exceptional ability to deliver extremely high doses that external beam radiotherapy (EBRT) could never achieve within treated lesions, with the added benefit that doses drop off rapidly outside the target lesion by minimizing the exposure of uninvolved surrounding normal tissue. Spurred by multiple biological and technological advances, BT application has experienced substantial alteration over the past few decades. The procedure of I-125 radioactive seed implantation evolved from ultrasound guidance to computed tomography guidance. Compellingly, the creative introduction of 3D-printed individual templates, BT treatment planning systems, and artificial intelligence navigator systems remarkably increased the accuracy of I-125 BT and individualized I-125 ablative radiotherapy. Of note, utilizing I-125 to treat carcinoma in hollow cavity organs was enabled by the utility of self-expandable metal stents (SEMSs). Initially, I-125 BT was only used in the treatment of rare tumors. However, an increasing number of clinical trials upheld the efficacy and safety of I-125 BT in almost all tumors. Therefore, this study aims to summarize the recent advances of I-125 BT in cancer therapy, which cover experimental research to clinical investigations, including the development of novel techniques. This review also raises unanswered questions that may prompt future clinical trials and experimental work.

show abstract

“…Despite the survival benefits of RT suggested in previous reports, this therapeutic approach is often limited by concerns about long‐term toxicity in children, such as xerostomia, trismus, development of secondary cancers, and craniofacial growth abnormalities 20,21 . 125 I interstitial brachytherapy (IBT) is an RT modality, where postoperative 125 I IBT delivers a high dose of radiation directly to target areas, minimizing nontarget dose dispersal to adjacent normal structures, and is increasingly reported as effective and safe for treating children with malignant PG tumors 22‐24 …”

Section: Introductionmentioning

confidence: 99%

“…20,21 125 I interstitial brachytherapy (IBT) is an RT modality, where postoperative 125 I IBT delivers a high dose of radiation directly to target areas, minimizing nontarget dose dispersal to adjacent normal structures, and is increasingly reported as effective and safe for treating children with malignant PG tumors. [22][23][24] The aim of this retrospective study was to analyze the effectiveness and safety of surgery combined with postoperative 125 I IBT among children and adolescents with AciCC of the PG with high-risk features.…”

mentioning

confidence: 99%

Efficacy of surgery combined with postoperative ¹²⁵I interstitial brachytherapy for treatment of acinic cell carcinoma of the parotid gland in children and adolescents

Zhang

Lyu

et al. 2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Background: Acinic cell carcinoma (AciCC) is rare in children; therefore, reaching a consensus on its management is challenging and radiotherapy is limited by concerns about long-term toxicity.The purpose of this study is to analyze the effectiveness and safety of surgery plus postoperative 125 I interstitial brachytherapy (IBT) for children and adolescents with AciCC of the parotid gland (PG) treated at a single institution.Procedure: Sixteen patients ≤ 18 years old with AciCC of the PG treated with surgery plus 125 I IBT from 2007 to 2018 were included. Surgery was the primary treatment; ten patients underwent total gross excision and six subtotal gross excision. The matched peripheral dose was 60-120 Gy.Overall survival, disease-free survival (DFS), local control rate, distant metastasis, and radiationassociated toxicities were analyzed, and factors influencing outcomes were evaluated.Results: During follow-up (1.8-12.6 years; mean, 6.3 years), lymph node metastasis was observed in one case, 2.6 years after 125 I IBT treatment. The five-year overall and DFS rates were 100% and 91.7%, respectively. On univariate analysis, tumor size ≥ 3 cm (100% vs 50%; P = 0.025) and extraglandular extension (100% vs 50%; P = 0.025) were significant prognostic indicators for DFS.No severe radiation-associated complications occurred. Conclusions:Children and adolescents with AciCC of the PG with high-risk features can be managed using surgery plus postoperative 125 I IBT with excellent local control. Radiation-related complications were minor. Patients with facial nerve involvement can have their facial nerves preserved. Residual tumors can be safely managed using adjuvant 125 I IBT. K E Y W O R D Sacinic cell carcinoma, adolescent, brachytherapy, children, parotid gland

show abstract

Efficacy of combined surgery and ¹²⁵I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Cited by 10 publications

References 20 publications

Mucoepidermoid carcinoma in the infratemporal fossa: A case report

Mucoepidermoid carcinoma in the infratemporal fossa: A case report

Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions

Efficacy of surgery combined with postoperative ¹²⁵I interstitial brachytherapy for treatment of acinic cell carcinoma of the parotid gland in children and adolescents

Contact Info

Product

Resources

About

Efficacy of combined surgery and 125I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Cited by 10 publications

References 20 publications

Mucoepidermoid carcinoma in the infratemporal fossa: A case report

Mucoepidermoid carcinoma in the infratemporal fossa: A case report

Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions

Efficacy of surgery combined with postoperative 125I interstitial brachytherapy for treatment of acinic cell carcinoma of the parotid gland in children and adolescents

Contact Info

Product

Resources

About

Efficacy of combined surgery and ¹²⁵I seed brachytherapy for treatment of primary mucoepidermoid carcinoma of the parotid gland

Efficacy of surgery combined with postoperative ¹²⁵I interstitial brachytherapy for treatment of acinic cell carcinoma of the parotid gland in children and adolescents